Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.62EUR
20 Jan 2017
Change (% chg)

€-0.15 (-0.20%)
Prev Close
€75.77
Open
€75.63
Day's High
€76.43
Day's Low
€75.20
Volume
3,349,301
Avg. Vol
2,831,407
52-wk High
€79.07
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and... (more)

Overall

Beta: 0.85
Market Cap(Mil.): €97,702.73
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.93
Yield (%): 3.87

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.46 29.51 30.38
EPS (TTM): 3.22 -- --
ROI: -- 15.44 14.86
ROE: -- 16.62 16.28

Sanofi's M&A misses frustrate some investors in drugmaker

PARIS/DAVOS, Switzerland For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker.

20 Jan 2017

Sanofi's M&A misses frustrate some investors in drugmaker

PARIS/DAVOS, Switzerland For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker.

20 Jan 2017

INSIGHT-Sanofi's M&A misses frustrate some investors in drugmaker

* Investors growing impatient after it fails to land acquisitions

20 Jan 2017

EpiPen rival to be offered free to many but high price for insurers

Privately held drugmaker Kaleo on Thursday said it would offer its Auvi-Q emergency allergy auto-injector at no cost to many consumers, but set a list price for the EpiPen rival that will be used as the benchmark cost to insurance companies at a whopping $4,500.

19 Jan 2017

EpiPen rival to be offered free to many but high price for insurers

Jan 19 Privately held drugmaker Kaleo on Thursday said it would offer its Auvi-Q emergency allergy auto-injector at no cost to many consumers, but set a list price for the EpiPen rival that will be used as the benchmark cost to insurance companies at a whopping $4,500.

19 Jan 2017

French state to keep stake in Peugeot-Citroen - president's office

PARIS, Jan 19 The French government will keep its stake in car maker PSA Peugeot Citroen, the office of president Francois Hollande tweeted on Thursday.

19 Jan 2017

BRIEF-Sanofi buys 87,298 shares of Regeneron's common stock on Jan 11

* Sanofi reports open market purchase of 87,298 shares of Regeneron Pharmaceuticals Inc's common stock on Jan 11 - SEC filing Source text: http://bit.ly/2iR2AXn Further company coverage:

13 Jan 2017

CORRECTED-Regeneron CEO says Amgen not putting patients first in patent dispute

Jan 9 Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

10 Jan 2017

BRIEF-Regeneron says Sanofi plant used to fill drugs now deemed acceptable

* Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable

10 Jan 2017

BRIEF-MannKind says receives $30.6 million from Sanofi

* MannKind receives $30.6 million from Sanofi Source text for Eikon: Further company coverage:

09 Jan 2017

Earnings vs. Estimates